Details of the Drug Combination

General Information of Drug Combination (ID: DCBAYGS)

Drug Combination Name
Levosimendan Magnesium Sulfate
Indication
Disease Entry Status REF
Aortic Coarctation Phase 4 [1]
Component Drugs Levosimendan   DMKBOS2 Magnesium Sulfate   DMVEK07
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Levosimendan
Disease Entry ICD 11 Status REF
Congestive heart failure BD10 Approved [2]
Heart failure BD10-BD13 Phase 4 [3]
Cardiac output syndrome BC43 Phase 3 [4]
Pulmonary hypertension BB01 Phase 2 [4]
Levosimendan Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Troponin C (TN-C) TT8RDXP TNNC1_HUMAN Stimulator [7]
------------------------------------------------------------------------------------
Indication(s) of Magnesium Sulfate
Disease Entry ICD 11 Status REF
Acute pain MG31 Approved [5]
Familial primary hypomagnesemia N.A. Approved [6]
Hypertension, pregnancy-induced N.A. Approved [6]
Mild pre-eclampsia N.A. Approved [6]
Non-arteritic anterior ischemic optic neuropathy 9C40.40 Approved [6]
Pain MG30-MG3Z Approved [6]
Severe pre-eclampsia N.A. Approved [6]
Traumatic brain injury NA07.Z Approved [6]
Magnesium Sulfate Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
N-methyl-D-aspartate receptor (NMDAR) TT9IK2Z NOUNIPROTAC Antagonist [8]
------------------------------------------------------------------------------------
Magnesium Sulfate Interacts with 4 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Kallikrein-8 (KLK8) OTGVGHXY KLK8_HUMAN Increases Activity [9]
Renin (REN) OT52GZR2 RENI_HUMAN Increases Activity [10]
Interleukin-1 beta (IL1B) OT0DWXXB IL1B_HUMAN Decreases Expression [11]
Interleukin-8 (CXCL8) OTS7T5VH IL8_HUMAN Increases Expression [11]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT04330755) Levosimendan Versus Combination With Magnesium Sulphate on Spine Protection by NIRS in Infants Undergoing Coarctectomy
2 Emerging drugs for acute and chronic heart failure: current and future developments. Expert Opin Emerg Drugs. 2007 Mar;12(1):75-95.
3 ClinicalTrials.gov (NCT04705337) Levosimendan In Ambulatory Heart Failure Patients (LEIA-HF). U.S. National Institutes of Health.
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5 Emerging drugs for acute ischemic stroke. Expert Opin Emerg Drugs. 2009 Mar;14(1):33-42.
6 Magnesium Sulfate FDA Label
7 Timing of levosimendan in cardiac surgery. Anadolu Kardiyol Derg. 2009 Jun;9(3):223-30.
8 Magnesium sulfate diminishes the effects of amide local anesthetics in rat sciatic-nerve block. Reg Anesth Pain Med. 2007 Jul-Aug;32(4):288-95.
9 Activation and enzymatic characterization of recombinant human kallikrein 8. Biol Chem. 2006 Jun;387(6):723-31. doi: 10.1515/BC.2006.091.
10 Haemodynamic and endocrine effects of deliberate hypotension with magnesium sulphate for cerebral-aneurysm surgery. Eur J Anaesthesiol. 1991 Mar;8(2):115-21.
11 Profiling the immunotoxicity of chemicals based on in vitro evaluation by a combination of the Multi-ImmunoTox assay and the IL-8 Luc assay. Arch Toxicol. 2018 Jun;92(6):2043-2054. doi: 10.1007/s00204-018-2199-7. Epub 2018 Mar 29.